Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to better treatment response. This trial aims to confirm earlier positive phase 2 results showing significant symptom improvement. Topline results are expected by the end of 2026, potentially offering the first targeted therapy for over 1.5 million moderate to severe DED patients in the US with this genetic profile.
Oculis Holding AG's PREDICT-1 trial on Licaminlimab targets a genetic variant found in two-thirds of enrolled patients. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 13:11 WIB: out of 150 priced US health stocks, 79 rose and 65 fell. Notable movers include Acadia Healthcare Company Inc (ACHC) at USD 29.98 with a -5.34% change and a typical hold time of 8 days, Dyne Therapeutics Inc. (DYN) at USD 14.25 with a -5.25% change and a 3-day hold time, and Davita Inc (DVA) at USD 190.05 with a +5.17% change and a 115-day hold time.
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
Primary Health Properties PLC has partnered with Singapore's GIC to create a £700 million joint venture comprising 27 private hospitals. The deal, expected to complete in November, will generate about £500 million in net proceeds for Primary Health P...
